KROS

11.02

0.27% 0.03

Dopo l'orario di chiusura: 11.02

Keros Therapeutics Inc (KROS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché KROS Giù? Forum Previsione

Precedente Chiudi:

$10.99

Aprire:

$11.02

Volume 24 ore:

516.56K

Relative Volume:

1.21

Capitalizzazione di mercato:

$217.29M

Reddito:

$244.06M

Utile/perdita netta:

$87.01M

Rapporto P/E:

6.0506

EPS:

1.8213

Flusso di cassa netto:

$105.95M

1 W Prestazione:

-2.48%

1M Prestazione:

-33.53%

6M Prestazione:

-29.63%

1 anno Prestazione:

-3.92%

Intervallo 1D:

$10.88

$11.35

Intervallo di 1 settimana:

$10.49

$11.74

Portata 52W:

$9.12

$22.55

Keros Therapeutics Inc Stock (KROS) Company Profile

Nome

Keros Therapeutics Inc

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

617-314-6297

Indirizzo

1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA

Dipendente

Cinguettio

Prossima data di guadagno

2026-02-27

Ultimi documenti SEC

KROS's Discussions on Twitter

Compare KROS vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
KROS Keros Therapeutics Inc	11.02	217.29M	244.06M	87.01M	105.95M	1.8213
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-10-20	Iniziato	Wells Fargo	Overweight
2025-06-10	Downgrade	BofA Securities	Buy → Neutral
2025-01-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2025-01-17	Downgrade	Wedbush	Outperform → Neutral
2024-12-16	Downgrade	Guggenheim	Buy → Neutral
2024-12-16	Reiterato	Oppenheimer	Outperform
2024-12-13	Reiterato	H.C. Wainwright	Buy
2024-12-12	Downgrade	BTIG Research	Buy → Neutral
2024-12-12	Downgrade	TD Cowen	Buy → Hold
2024-12-12	Downgrade	William Blair	Outperform → Mkt Perform
2024-11-05	Iniziato	Jefferies	Buy
2024-10-24	Iniziato	Cantor Fitzgerald	Overweight
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-09-23	Iniziato	Guggenheim	Buy
2024-06-25	Iniziato	Oppenheimer	Outperform
2024-02-21	Iniziato	William Blair	Outperform
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-07-31	Iniziato	Wedbush	Outperform
2023-07-26	Iniziato	BofA Securities	Buy
2023-02-14	Iniziato	Cowen	Outperform
2022-10-18	Iniziato	Truist	Buy
2022-07-26	Iniziato	BTIG Research	Buy
2020-12-08	Reiterato	H.C. Wainwright	Buy
2020-05-04	Iniziato	H.C. Wainwright	Buy
2020-05-04	Iniziato	Jefferies	Buy
2020-05-04	Iniziato	Piper Sandler	Overweight
2020-05-04	Iniziato	SVB Leerink	Outperform

Mostra tutto

Keros Therapeutics Inc Borsa (KROS) Ultime notizie

Mar 13, 2026

Keros Therapeutics (NASDAQ:KROS) Gains Market Attention In Nasdaq Index - Kalkine Media

Mar 13, 2026

Mar 12, 2026

Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart

Mar 12, 2026

Myelofibrosis Market: Strong Pharma Growth Forecast Through - openPR.com

Mar 12, 2026

Mar 11, 2026

Technical Reactions to KROS Trends in Macro Strategies - Stock Traders Daily

Mar 11, 2026

Mar 09, 2026

Keros Therapeutics Partners with Healey & AMG Center for ALS to Launch Phase 2 Trial of Rinvatercept for ALS Treatment - Minichart

Mar 09, 2026

Keros Therapeutics Advances Rinvatercept in ALS Collaboration - TipRanks

Mar 09, 2026

Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference - Bitget

Mar 09, 2026

Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS - The Manila Times

Mar 09, 2026

Keros Therapeutics to Test Rinvatercept in Phase 2 ALS Trial with Mass General; Phase 1 Data Presented - TradingView

Mar 09, 2026

Personalized ALS trial to test Keros rinvatercept at Mass General - Stock Titan

Mar 09, 2026

Q1 EPS Estimate for Keros Therapeutics Decreased by Analyst - MarketBeat

Mar 09, 2026

Mar 07, 2026

Sell Signal: Does Keros Therapeutics Inc stock reflect fundamentals2025 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn

Mar 07, 2026

Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? - The Globe and Mail

Mar 07, 2026

Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen - MarketBeat

Mar 07, 2026

Is Keros Therapeutics Inc vulnerable to short sellers2025 Price Targets & Weekly Sector Rotation Insights - baoquankhu1.vn

Mar 07, 2026

Can Keros Therapeutics Inc be the next market leaderM&A Rumor & Daily Technical Stock Forecast Reports - baoquankhu1.vn

Mar 07, 2026

Is Keros Therapeutics Inc. stock a buy before product launchesPortfolio Value Summary & Growth Focused Stock Reports - Naître et grandir

Mar 07, 2026

Mar 06, 2026

Investment Review: Is now the right time to enter Keros Therapeutics IncChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn

Mar 06, 2026

Can Keros Therapeutics' Rinvatercept Distinguish Itself in the DMD Marketplace? - Bitget

Mar 06, 2026

What is HC Wainwright's Estimate for KROS FY2030 Earnings? - MarketBeat

Mar 06, 2026

Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility - TipRanks

Mar 06, 2026

Mar 05, 2026

Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00 - MarketBeat

Mar 05, 2026

Wells Fargo Maintains "Overweight" on Keros Therapeutics (KROS), Lowers Price Target | KROS Stock News - GuruFocus

Mar 05, 2026

Keros Therapeutics Reports FY25 Results, Highlights Progress Across Hematology And Muscle Pipeline - Nasdaq

Mar 05, 2026

Mar 04, 2026